한양대학교 · Medicine
다이 원 준 교수의 연구실은 간질환, 특히 비알코올성간지방증(MASLD/NAFLD)과 간섬유화의 병태생리적 기전을 밝히는 데 초점을 맞추고 있습니다. 장내 미생물총 조절을 통한 대사성 간질환 예방 및 치료 전략, 특히 프로바이오틱스와 항산화 물질(카니틴, 루티논 등)의 기전적 영향을 중심으로 연구를 진행하고 있습니다. 또한 간내 염증, 지방침착, 미토콘드리아 기능 이상 등 대사성 간손상의 핵심 메커니즘을 규명하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The intestinal microbiota is closely associated with the development of obesity and nonalcoholic fatty liver disease (NAFLD). This study investigated the effects of probiotic treatment on visceral fat area (VFA) and intrahepatic fat (IHF) fraction in NAFLD. Sixty-eight obese NAFLD patients (>5% proton density fat fraction [PDFF] on magnetic resonance imaging [MRI]) were randomized to probiotic and placebo groups for 12 weeks. The probiotic mixture included 6 bacterial species. VFA and IHF were m
Caffeine attenuates the progression of liver fibrosis by inhibiting HSCs adhesion and activation.
We conclude that short-term probiotic administration in chronic liver disease is effective in alleviating SIBO and clinical symptoms, but ineffective in improving intestinal permeability and liver function.
Almost all the patients with NAFLD met the new criteria for MASLD. The fibrosis burden of the MetALD group was higher than those of the MASLD and ALD groups.
Carnitine and carnitine-lipoic acid prevent lipotoxicity by increasing mitochondrial β-oxidation and reducing intracellular oxidative stress.
Intrahepatic inflammation and metabolic derangements were more prominent in the HF and HFr combination model than in the HF monodiet model.
Several hepatic steatosis formulae have been validated in various cohorts using ultrasonography. However, none of these studies has been validated in a community-based setting using the gold standard method. Thus, the aim of this study was to externally validate hepatic steatosis formulae in community-based settings using magnetic resonance imaging (MRI). A total of 1301 community-based health checkup subjects who underwent liver fat quantification with MRI were enrolled in this study. Diagnosti
Mixed lineage kinase domain-like pseudokinase inhibition has protective effects in non-alcoholic steatohepatitis by decreasing hepatic de novo fat synthesis and chemokine (C-X-C motif) ligand expressions.
5-HT2A receptor antagonists can reduce inflammation and the activation of HSCs in this cirrhotic model.
